ISRCTN52580708 · RECRUITING

The effectiveness of a supplement containing standardized Cosmos caudatus extract on memory, mood and cognitive-related biomarkers in the ageing population with mild cognitive impairment

This trial is testing whether a daily capsule made from Cosmos caudatus, a Malaysian leafy plant, improves memory, mood, and blood markers linked to thinking in people with mild cognitive impairment. Participants take it for 24 weeks versus a placebo. The source lists no phase, so it is early-stage research, not proven or approved.

Eligibility criteria

Inclusion Criteria:
1. Malaysians aged 50 years and above with body mass index (BMI) 20-30 kg/m²
2. Montreal Cognitive Assessment (MoCA) scores ≤23
3. Have no or very minimal limitations in instrumental activities of daily living (IADL) with a score of ≤1.5 SD from mean norm
4. Objective memory impairment with a score of at least 1.5 SD below the mean average in one or more cognitive test (Rey Auditory Verbal Learning Test (RAVLT) (immediate recall) or Digit Span)
5. Self- and informant-reported memory complaints
6. Able to communicate and understand Malay or English language
Exclusion Criteria:
1. Individuals diagnosed with neurodegenerative conditions, severe depression and compulsive substance use
2. Individuals with chronic disease (diabetic patient on medication, chronic kidney disease, hepatitis/liver cirrhosis, cancer)
3. Individuals with physical disability
4. Female participants receiving ongoing hormone replacement therapy (HRT)
Functional magnetic resonance imaging (fMRI) subsample:
1. Individuals with ferromagnetic or non-ferrous implanted materials
2. Individuals with claustrophobia
3. Individuals with color blindness

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2026-09-14

View full record on ISRCTN

Source: ISRCTN registry, record ISRCTN52580708, retrieved 2026-10-27. Registry text licensed CC BY 4.0.

All APOE4 clinical trials